Compare Crispr Therapeutics AG (CRSP) vs Mongodb Inc (MDB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Mongodb Inc — how do they compare? Crispr Therapeutics AG trades at $51.11 (market cap $4.88B), while Mongodb Inc trades at $374.06 (market cap $29.24B). The key difference: Mongodb Inc is far larger — about 6× Crispr Therapeutics AG's market cap, and Mongodb Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Mongodb Inc for 45 Days on average.
| CRSP | MDB | |
|---|---|---|
Market Cap | $4.88B | $29.24B |
Volume | 2,861,747 | 1,304,995 |
Sector | Health | Technology |
52-Week High | $74.92 | $472.29 |
52-Week Low | $44.34 | $225.95 |
Typical Hold Time | 77 Days | 45 Days |
Enterprise Value | $3.30B | $26.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% on the day, with a bearish technical signal and negative profitability metrics. The company reported no revenue in 2025 with a net loss of $581.60M, though recent earnings beat expectations in Q2 2026. Analyst sentiment remains positive with a $67.83 price target and 57.9% buy ratings, supported by upcoming clinical data catalysts for its gene-editing therapies.
The stock faces significant fundamental challenges with negative margins and cash burn, but strong analyst support and pipeline progress offer long-term potential. Key risks include clinical trial outcomes and commercialization execution, while institutional interest and positive media coverage provide near-term catalysts for investor consideration.
MongoDB (MDB) trades at $363.03, up 0.64% today, with a bearish technical signal despite recent positive earnings beats. The company reported strong revenue growth, reaching $2.01 billion in 2025, but remains unprofitable with a net loss of $129.07 million. Recent news highlights AI product launches and a CEO transition, with analysts maintaining a bullish consensus price target of $456.76.
The outlook is mixed: strong revenue growth and AI initiatives offer upside, but high valuation ratios and persistent losses pose risks. Investor sentiment is cautiously optimistic, though technical indicators suggest near-term pressure. Key risks include execution challenges and competitive threats in the database market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →
